Education
About Us
Working with TipRanks
Follow Us
Xilio Therapeutics (XLO)
NASDAQ:XLO
XLO Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.58 - $1.93
Previous CloseN/A
Volume162.24K
Average Volume (3M)7.53M
Market Cap
$40.90M
Enterprise Value-$2.85M
Total Cash (Recent Filing)$55.29M
Total Debt (Recent Filing)$8.14M
Price to Earnings (P/E)―
Beta-0.71
Next Earnings
May 07, 2025EPS Estimate
0.19Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.28
Shares Outstanding51,773,716
10 Day Avg. Volume520,949
30 Day Avg. Volume7,526,411
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)6.45
Price to Cash Flow (P/CF)-0.70
P/FCF Ratio0.00
Enterprise Value/Market Cap-0.07
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-0.45
Enterprise Value/Ebitda0.05
Forecast
1Y Price Target
$4.50Price Target Upside476.92% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
---
Xilio Therapeutics News
---
Bulls Say, Bears Say
Bulls Say
Clinical Trial ResultsThe vilastobart combination therapy also demonstrates a better safety and tolerability profile compared to competing therapies.
CollaborationThe collaboration agreement with AbbVie further validates Xilio's capabilities and notably extends the cash runway.
Pipeline DevelopmentXilio plans to nominate multiple development candidates for its ATACR and SEECR platforms over the next few years, indicating a strong pipeline.
Bears Say
Clinical Trial ChallengesXTX-202 was being tested in a Phase I/II trial with expansion cohorts in melanoma/RCC. However, the monotherapy program was ultimately discontinued due to modest efficacy.
Financial OutlookCurrent cash supports operations through 2Q25, providing financial stability for continued development.
---
Risk Analysis
Main Risk Category
Legal & RegulatoryLitigation, compliance, new legislation, and taxation risks
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
XLO FAQ
What was Xilio Therapeutics’s price range in the past 12 months?
Xilio Therapeutics lowest stock price was $0.58 and its highest was $1.93 in the past 12 months.
What is Xilio Therapeutics’s market cap?
Xilio Therapeutics’s market cap is $40.90M.
When is Xilio Therapeutics’s upcoming earnings report date?
Xilio Therapeutics’s upcoming earnings report date is May 07, 2025 which is in 42 days.
How were Xilio Therapeutics’s earnings last quarter?
Xilio Therapeutics released its earnings results on Mar 11, 2025. The company reported -$0.2 earnings per share for the quarter, beating the consensus estimate of -$0.217 by $0.017.
Is Xilio Therapeutics overvalued?
According to Wall Street analysts Xilio Therapeutics’s price is currently Undervalued.
Does Xilio Therapeutics pay dividends?
Xilio Therapeutics does not currently pay dividends.
What is Xilio Therapeutics’s EPS estimate?
Xilio Therapeutics’s EPS estimate is 0.19.
How many shares outstanding does Xilio Therapeutics have?
Xilio Therapeutics has 51,773,716 shares outstanding.
What happened to Xilio Therapeutics’s price movement after its last earnings report?
Xilio Therapeutics reported an EPS of -$0.2 in its last earnings report, beating expectations of -$0.217. Following the earnings report the stock price went down -5.952%.
Which hedge fund is a major shareholder of Xilio Therapeutics?
Currently, no hedge funds are holding shares in XLO
---
Xilio Therapeutics Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$4.50 (476.92% Upside)
$4.50 (476.92% Upside)
Hedge Fund Trend
Decreased
By 3.7M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $1.8M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 3.9%
Last 30 Days ▼ 13.7%
Last 30 Days ▼ 13.7%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
11.03%
12-Months-Change
Fundamentals
Return on Equity
-214.02%
Trailing 12-Months
Asset Growth
16.66%
Trailing 12-Months
Company Description
Xilio Therapeutics
Xilio Therapeutics, Inc., a clinical-stage biotechnology company, develops immunotherapies to improve the immune system of cancer patients. Its checkpoint inhibitor program includes XTX101, a clinical-stage, tumor-selective anti-CTLA-4 mAb that is in Phase 1/2 clinical trials in patients with solid tumors. The company also develops cytokine programs, which comprises XTX202, a modified form of IL-2; XTX301, an IL-12 product candidate; and XTX401, an IL-15 product candidate that are masked with a protein domain to prevent binding activity until cleaved off by tumor microenvironment (TME)-associated proteases. Xilio Therapeutics, Inc. was founded in 2016 and is headquartered in Waltham, Massachusetts.
---
XLO Stock 12 Month Forecast
Average Price Target
$4.50
▲(476.92% Upside)
Technical Analysis
Karyopharm Therapeutics
―
Immatics
―
ALX Oncology Holdings
―
Tango Therapeutics
―
Foghorn Therapeutics
―
Best Analysts Covering XLO
1 Year
1 Year Success Rate
1/8 ratings generated profit
1 Year Average Return
-40.50%
reiterated a buy rating 16 days ago
Copying Michael Ulz's trades and holding each position for 1 Year would result in 12.50% of your transactions generating a profit, with an average return of -40.50% per trade.
---